The New Era of First-Line Immunotherapy for Advanced NSCLC – Medscape
|
The New Era of First-Line Immunotherapy for Advanced NSCLC
Medscape As valuable as it has been to get new approvals for patients with previously treated advanced non–small cell lung cancer (NSCLC), as described recently, the stakes are even higher when a new therapy is approved in the first-line setting. With the … |
